Zevra Therapeutics, Inc. (ZVRA)Healthcare | Biotechnology | Boston, United States | NasdaqGS
11.85 USD
+0.11
(0.937%)
⇧
(Aug. 27, 2026, 4 p.m.
EDT)
After hours: 11.71 -0.14 (-0.140%) ⇩ (Aug. 27, 2026, 7:30 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 3:09 a.m. EDT
The investment case for Zevra is currently paralyzed by a severe disconnect between its pristine balance sheet and its deteriorating market reality. Fundamentally, the company holds a fortress-like position with negligible debt, massive cash reserves, and robust profitability metrics, yet the stock has suffered an 88% collapse over the last nine years. This long-term trajectory is not a temporary dislocation but a structural verdict by the market on the efficacy of its core asset, Arimoclomol, following the European Medicines Agency's rejection of its bid for Niemann-Pick Type C. While the recent surge in call volume suggests traders are hoping for a miraculous regulatory turnaround or new data to reverse this trend, the overwhelming put writing indicates that the majority of capital is betting against further downside. With no dividend to provide income and a history of repeated failures in key markets, the risk-reward profile remains skewed heavily toward the downside until the company can demonstrate a definitive path to commercial success in major jurisdictions. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.099072 |
| AutoETS | 0.099072 |
| MSTL | 0.099406 |
| AutoTheta | 0.102773 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 38% |
| H-stat | 2.71 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.206 |
| Excess Kurtosis | -0.67 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 0.687 |
| Revenue per Share | 2.367 |
| Market Cap | 703,697,792 |
| Trailing P/E | 12.74 |
| Forward P/E | 11.29 |
| Beta | 0.92 |
| Profit Margins | 42.82% |
| Website | https://www.zevra.com |
As of Aug. 22, 2026, 3:09 a.m. EDT: Speculators are positioning defensively with heavy put volume and open interest at strikes significantly below the current price (e.g., $8.00 and $5.00 for December expirations), creating a 'floor' scenario. Conversely, call activity is concentrated near the money ($12.00-$13.00) with notable new flow at distant strikes ($20.00), suggesting a binary bet on regulatory approval or clinical data rather than a linear price appreciation thesis. Implied volatility is elevated relative to historical norms, reflecting uncertainty surrounding the recent European rejection.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.30650496 |
| Address1 | 101 Federal Street |
| Address2 | Suite 103 |
| All Time High | 418.4 |
| All Time Low | 1.936 |
| Ask | 14.98 |
| Ask Size | 2 |
| Audit Risk | 8 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 797,090 |
| Average Daily Volume3 Month | 1,525,892 |
| Average Volume | 1,525,892 |
| Average Volume10Days | 797,090 |
| Beta | 0.923 |
| Bid | 8.54 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 3.668 |
| City | Boston |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 11.85 |
| Current Ratio | 5.167 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 11.91 |
| Day Low | 11.6211 |
| Debt To Equity | 0.687 |
| Display Name | Zevra Therapeutics |
| Dividend Date | 1,609,113,600 |
| Earnings Call Timestamp End | 1,785,961,800 |
| Earnings Call Timestamp Start | 1,785,961,800 |
| Earnings Growth | -0.884 |
| Earnings Quarterly Growth | -0.883 |
| Earnings Timestamp | 1,785,960,000 |
| Earnings Timestamp End | 1,793,822,400 |
| Earnings Timestamp Start | 1,793,822,400 |
| Ebitda | 40,553,000 |
| Ebitda Margins | 0.29803 |
| Enterprise To Ebitda | 11.926 |
| Enterprise To Revenue | 3.554 |
| Enterprise Value | 483,623,808 |
| Eps Current Year | 1.14 |
| Eps Forward | 1.05 |
| Eps Trailing Twelve Months | 0.93 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 12.1384 |
| Fifty Day Average Change | -0.2883997 |
| Fifty Day Average Change Percent | -0.023759285 |
| Fifty Two Week Change Percent | 30.650497 |
| Fifty Two Week High | 15.035 |
| Fifty Two Week High Change | -3.1849995 |
| Fifty Two Week High Change Percent | -0.211839 |
| Fifty Two Week Low | 7.16 |
| Fifty Two Week Low Change | 4.6900005 |
| Fifty Two Week Low Change Percent | 0.65502805 |
| Fifty Two Week Range | 7.16 - 15.035 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,429,191,000,000 |
| Float Shares | 53,902,658 |
| Forward Eps | 1.05 |
| Forward P E | 11.285715 |
| Free Cashflow | 48,381,124 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 61 |
| Fullday Change | 0.110001 |
| Fullday Change Percent | 0.936973 |
| Fullday Price | 11.71 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,785,542,400 |
| Gross Margins | 0.95458 |
| Gross Profits | 129,891,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.01258 |
| Held Percent Institutions | 0.77142996 |
| Implied Shares Outstanding | 59,383,781 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,609,113,600 |
| Last Split Factor | 1:16 |
| Long Business Summary | Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts. |
| Long Name | Zevra Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 703,697,792 |
| Market State | POSTPOST |
| Max Age | 86,400 |
| Message Board Id | finmb_65059726 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 57,247,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 697,462,507 |
| Number Of Analyst Opinions | 9 |
| Open | 11.74 |
| Operating Cashflow | 33,399,000 |
| Operating Margins | 0.42299 |
| Overall Risk | 8 |
| Payout Ratio | 0.0 |
| Peg Ratio | 10.67 |
| Phone | 888 958 1253 |
| Post Market Change | -0.14000034 |
| Post Market Change Percent | -1.1814375 |
| Post Market Price | 11.71 |
| Post Market Time | 1,787,873,403 |
| Previous Close | 11.74 |
| Price Eps Current Year | 10.394737 |
| Price Hint | 2 |
| Price To Book | 3.2306435 |
| Price To Sales Trailing12 Months | 5.1715484 |
| Profit Margins | 0.42818 |
| Quick Ratio | 5.018 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.22222 |
| Region | US |
| Regular Market Change | 0.110001 |
| Regular Market Change Percent | 0.936973 |
| Regular Market Day High | 11.91 |
| Regular Market Day Low | 11.6211 |
| Regular Market Day Range | 11.6211 - 11.91 |
| Regular Market Open | 11.74 |
| Regular Market Previous Close | 11.74 |
| Regular Market Price | 11.85 |
| Regular Market Time | 1,787,860,800 |
| Regular Market Volume | 620,421 |
| Return On Assets | 0.08736 |
| Return On Equity | 0.34796003 |
| Revenue Growth | 0.533 |
| Revenue Per Share | 2.367 |
| Sand P52 Week Change | 0.1890428 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 59,383,781 |
| Shares Percent Shares Out | 0.109 |
| Shares Short | 6,470,662 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 7,795,667 |
| Short Name | Zevra Therapeutics, Inc. |
| Short Percent Of Float | 0.1102 |
| Short Ratio | 4.73 |
| Source Interval | 15 |
| State | MA |
| Symbol | ZVRA |
| Target High Price | 35.0 |
| Target Low Price | 20.0 |
| Target Mean Price | 25.0 |
| Target Median Price | 24.0 |
| Total Cash | 221,570,000 |
| Total Cash Per Share | 3.731 |
| Total Debt | 1,496,000 |
| Total Revenue | 136,071,008 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 0.93 |
| Trailing P E | 12.741936 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 10.200475 |
| Two Hundred Day Average Change | 1.6495256 |
| Two Hundred Day Average Change Percent | 0.16171068 |
| Type Disp | Equity |
| Volume | 620,421 |
| Website | https://www.zevra.com |
| Zip | 2,110 |